Epilepsy Program

About GliaPharm

GliaPharm is a private, preclinical-stage biotech leveraging decades of glial cell research to develop neuroprotective therapies. The company has established the GliaX technology platform to discover and develop small molecules targeting glial cells, with an initial focus on Alzheimer's disease, epilepsy, and ALS. Backed by a strong scientific foundation from co-founder Prof. Pierre Magistretti and led by an experienced executive team, the company has secured non-dilutive funding, including a $4.2M investment from the Alzheimer's Drug Discovery Foundation (ADDF) in 2023. GliaPharm represents a novel approach in neurology by targeting non-neuronal cells, aiming to address high-unmet-need conditions with limited treatment options.

About Current Surgical

Current Surgical is a private, pre-revenue medical device startup founded in 2016, building a foundational platform for the next generation of minimally invasive, digital surgery. Its core technology integrates AI-processed real-time imaging with precision focused ultrasound ablation in a closed-loop control system, initially targeting early-stage solid tumor ablation. The company has a clear multi-year pipeline to expand into cardiac, pain, and neurological markets, is backed by elite investors like True Ventures, and has secured non-dilutive funding from the NIH and NSF to advance its platform.

About Bright Minds Biosciences

Bright Minds Biosciences is a mission-driven biotech focused on transforming treatment paradigms in CNS disorders through precision targeting of serotonin receptors. Founded in 2017, the company has rapidly advanced a proprietary platform to develop selective 5-HT2A and 5-HT2C agonists, deliberately engineered to avoid cardiotoxic 5-HT2B activity. Its strategy centers on de-risking clinical development through rigorous preclinical science and a deep, experienced leadership team. As a public company, it is positioned to leverage clinical milestones to address large, underserved markets in neurology and psychiatry.

About Lunai Bioworks

Lunai Bioworks is a public biotech company (LNAI) on a mission to decode disease biology by creating a continuous, integrated system where AI-driven insights are rapidly validated in living models. Founded in 2021, the company has developed a validated platform combining its Augusta AI engine, Phenograph translational system, and high-throughput zebrafish models to identify novel therapeutic targets and biomarkers. Its strategy focuses on advancing internal programs and strategic partnerships in complex therapeutic areas like oncology and neurology, aiming to compress drug discovery timelines and reduce clinical attrition.

Therapeutic Areas